PCR Oncology

Publications

Overall Survival with Osimertinib in Untreated, EGFR -Mutated Advanced NSCLC

Suresh S. Ramalingam , Johan Vansteenkiste , David Planchard +21 more

Among patients with previously untreated advanced NSCLC with an EGFR mutation, those who received osimertinib had longer overall survival than those who received a compar...

2019 New England Journal of Medicine 2577 citations

Osimertinib in Resected EGFR -Mutated Non–Small-Cell Lung Cancer

Yi‐Long Wu , Masahiro Tsuboi , Jie He +21 more

In patients with stage IB to IIIA EGFR mutation-positive NSCLC, disease-free survival was significantly longer among those who received osimertinib than among those who r...

2020 New England Journal of Medicine 1609 citations

Affiliated Researchers

Institution Info

Type: healthcare
Country: US
Publications: 2
Citations: 4,186

External Links

Identifiers

ROR: https://ror.org/013f5rs96

Publications

Overall Survival with Osimertinib in Untreated, <i>EGFR</i> -Mutated Advanced NSCLC

Osimertinib in Resected <i>EGFR</i> -Mutated Non–Small-Cell Lung Cancer

Affiliated Researchers

Matilde Saggese

Yuri Rukazenkov

Ajlan Atasoy

Institution Info

External Links

Identifiers